A. Reza Saadat has over 13 years of experience in the pharmaceutical industry as a scientist and in finance/business development capacities. He is the managing partner at Centius, a life science consulting firm located in Boston, Massachusetts.
Visit his site: Biotechnology Stock
A. Reza Saadat's Latest Articles
-
Vertex's Telaprevir May Become a Multi-Billion Dollar Drug
on Apr 02, 2008
about
VRTX
-
Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership
on Mar 27, 2008
about
ARNA
-
2007 Biotech Performance Review
-
Pharma, Biotech Present Great Investment Opportunities in 2008
-
Biogen-Idec Looks Good Once Again
on Dec 14, 2007
about
BIIB
-
Onyx's Cancer Drug: Potential Blockbuster - But With Competition
on Nov 26, 2007
about
ONXX
-
Retail Investors Should Grasp Opportunity In Vertex Pharmaceuticals
on Oct 23, 2007
about
VRTX
-
A Buyout Is No Certainty For Biogen-Idec
on Oct 17, 2007
about
BIIB
-
Genzyme Breaks Out On Good News
on Oct 08, 2007
about
GENZ
-
Pharmasset's Hepatitis C Drug Has A Promising Future
on Oct 05, 2007
about
VRUS
-
Biotech Product Developments Should Make 2008 More Eventful Than 2007
-
Altus Pharmaceuticals Makes Clinical And Financial Progress
on Jun 01, 2007
about
ALTU
-
Vertex Pharmaceutical's Hepatitis Drug Proves Effective, But Path To Market Unclear
on May 31, 2007
about
VRTX
Become a Contributor
Submit an Article
Research Stocks
Type in a stock or ETF symbol
to get:
- Earnings Call Transcripts
- Opinion and Analysis
- Quote and Chart
Latest Commentson A. Reza Saadat's Articles